Over the past hundred years, medicine has treated aging and cancer as two completely separate fronts. Aging researchers asked: Why do our cells lose function over time?. Cancer researchers asked: Why do certain cells start dividing uncontrollably? The assumption was that these two questions are fundamentally different, and therefore require different therapeutic approaches.
But the new review published in Donga Science, the Korean science daily, on April 7, 2026, reveals a different picture: Zombie cells and cancer are two sides of the same biological coin. Cellular senescence, the process where a cell stops dividing but doesn't die, is both the body's first defense against cancer and the factor that accelerates tumor emergence in old age. This understanding opens a new therapeutic approach called oncological senolytics, which harnesses senescence as a double-edged weapon.
What are Zombie Cells and Cancer: A Dual Definition
To understand the new approach, one must recall what zombie cells are and their connection to cancer:
- Zombie Cells (Senescent): Cells that have stopped dividing due to DNA damage, oxidative stress, or telomere erosion. They don't die, don't divide, and secrete inflammatory substances called SASP.
- Senescence as an Anti-Cancer Mechanism: When a cell acquires a dangerous mutation, its natural genes (like p53 and p16) may trigger senescence. This prevents the cell from becoming a tumor.
- The Paradox: Over time, senescent cells accumulate. Their inflammatory secretion damages neighboring tissues and the immune system, creating an environment that actually promotes tumor growth.
- Cancer Itself Can Undergo Senescence: Chemotherapy and radiation cause some cancer cells to enter senescence instead of dying. Such cells can later awaken and cause relapse.
This connection is far more complex than 'zombie cells cause cancer'. Senescence is both a protector and a threat, depending on timing and context.
The Connection to Oncological Senolytics: Two Opposing Approaches
The Korean review highlights two strategies developing in parallel in 2026, targeting different sides of the same biology.
First Approach: Clearing Senescent Cells to Prevent Cancer
This approach is based on the insight that senescent cells in old age create a chronic inflammatory environment that promotes mutations and fosters tumor development. The solution: administer senolytic drugs that identify and eliminate senescent cells, thereby clearing the 'pre-cancerous field' before a tumor even appears.
Drugs like dasatinib + quercetin (D+Q), fisetin, and a new generation (UBX0101, FOXO4-DRI) have shown in preclinical studies the ability to reduce the senescent cell burden by up to 50%. In aged mice, such clearance reduced the rate of spontaneous tumor emergence by 30-40%.
Second Approach: Inducing Senescence in Cancer Cells and Then Clearing Them
This is the opposite approach. Instead of preventing cancer, it treats existing cancer. The idea: administer a drug that forces senescence on active cancer cells, turning them from 'uncontrollably dividing tumor cells' into 'non-dividing zombie cells'. Then, administer a senolytic drug that clears the newly formed senescent cells.
This approach is called the One-Two Punch. The first step (induction) freezes the tumor in place. The second step (clearance) eliminates it. The advantage: cancer cells resistant to standard chemotherapy are often still sensitive to senescence induction.
Current Evidence
Study 1: Pancreatic Cancer, Team Carl Sherr, Memorial Sloan Kettering 2025
An American research group tested the dual approach in a mouse model of KRAS-mutant pancreatic cancer, one of the deadliest cancer types. First, they gave trametinib, a MEK inhibitor that induces senescence in cancer cells. Then, five days later, a senolytic. Survival rates increased from 15% to 67% within 12 months. Tumors resistant to standard chemotherapy responded to the dual treatment.
Study 2: Phase II Clinical Trial, Senescence in Melanoma 2026
A team from the Dana-Farber Cancer Institute completed a Phase II trial where 78 patients with advanced melanoma received a combination of a CDK4/6 inhibitor (palbociclib) followed by a senolytic. The response rate was 52%, compared to 28% with the CDK4/6 inhibitor alone. Side effects remained within acceptable limits.
Study 3: Mouse Model of Prevention, Mayo Clinic 2025
Mayo researchers, led by James Kirkland, followed 600 aged mice receiving fisetin twice a month versus a control group. Within 18 months, the tumor emergence rate in the fisetin group was 22% compared to 41% in the control. Cancer risk decreased by 46%. The first clear evidence that preventive clearance of zombie cells can reduce cancer incidence.
Study 4: Dual Approach to Lung Cancer, Seoul National University 2026
A Korean team tested the approach in NSCLC (non-small cell lung cancer). They used low-dose etoposide to trigger senescence, followed by navitoclax as a senolytic. Tumors shrank by 65% in mice, compared to 30% in the chemotherapy-only group. Researchers are now considering a Phase I trial in humans.
Study 5: Retrospective Review, Cancer Patients and Senolytics
A review published in Nature Reviews Cancer analyzed 43 preclinical studies of the dual approach. The average efficacy was a doubling of the therapeutic response rate compared to standard chemotherapy. Particularly in leukemias, hormone-resistant breast cancer, and pancreatic cancer.
What About Specific Cancer Types?
The dual-action approach is not equally suitable for all cancer types. The Korean review notes where it looks most promising and where less so:
- Pancreatic Cancer: One of the hottest areas. These tumors are almost always resistant to standard chemotherapy, and the dual approach offers a new option.
- Hormone-Resistant Breast Cancer: CDK4/6 inhibitors are already used clinically. Adding a senolytic afterward seems a natural solution.
- Melanoma: Tumors with BRAF/NRAS mutations respond well to senescence induction followed by clearance.
- Leukemias: The first senolytic drugs (dasatinib) were originally developed for leukemia. A natural synergy.
- Lung Cancer: Promising, but complex due to tumor heterogeneity.
- Brain Cancer (Glioblastoma): Limited success, due to the blood-brain barrier hindering drug delivery.
- Prostate Cancer: Mixed results. In some cases, senescence actually contributed to hormone resistance.
Should We Start Taking Senolytics?
This is the critical question, and it has several layers to understand.
If You Are a Healthy Person with No Cancer History
Evidence for cancer prevention with senolytics is primarily based on mice. In humans, there are no large randomized controlled trials yet proving that clearing zombie cells reduces cancer risk. Human studies of fisetin and D+Q are ongoing, but results will only come in 2-4 years. Caution is advised.
If You Are a Cancer Patient Undergoing Active Treatment
Do not take senolytics on your own. Timing is critical in the dual approach. A senolytic before the senescence induction phase can harm treatment. Only an oncologist can correctly time the combination. If your medical team is unfamiliar with the approach, ask for a referral to a center conducting clinical trials in this field.
If You Are a Cancer Survivor
This is a complex population. Senescent cells can remain after chemotherapy and cause late relapse. Senolytics theoretically offer an option to eliminate them, but safety in survivors has not yet been proven in large trials. Discuss with your oncologist before starting any supplement.
Side Effects and Risks
First-generation senolytics (dasatinib) are prescription drugs with significant side effects: nausea (35%), fatigue (28%), electrolyte disturbances (15%), temporary immune function decline. Fisetin is a supplement in experimental clinical use, considered relatively safe, but the high doses (1500-2000mg) used in studies differ from doses in commercial supplements.
What to Take Away from the Research?
- Understand that senescence is not just 'bad'. It is the body's first defense against cancer. The goal is not to eliminate all senescence, but to manage it wisely according to stage and timing.
- If diagnosed with cancer, ask about clinical trials of oncological senolytics. In 2026, there are dozens of active trials worldwide. Centers like MD Anderson, Memorial Sloan Kettering, and in Israel, Sheba and Ichilov, offer access to experimental treatments.
- Support your body's natural senescence. Intermittent fasting, physical activity, and adequate sleep all activate genes that identify potential cancer cells and push them into senescence.
- Adhere to routine screening tests. Early detection of tumors remains the most important tool for preventing mortality. Mammography, colonoscopy, PSA, skin checks, and for smokers, lung scans.
- Don't believe advertisements for 'miracle senolytic' supplements. Most commercially sold products are not yet proven. Fisetin is an exception with several Phase I studies, but it also requires high, monitored dosing.
- If you are in a family with a genetic predisposition to cancer (BRCA1/2, Lynch syndrome, etc.), consult a specialist about the possibility of joining prevention studies with senolytics.
The Broader Perspective
The dual-action approach to zombie cells and cancer signifies a conceptual shift. For a hundred years, cancer medicine was a direct war: identify the cancer cell, eliminate it. Now, we are learning to change the battlefield: reshape the cellular environment so that tumors struggle to appear and survive.
The Korean review in Donga Science puts it well: Cancer is a disease of aging, and treating it requires understanding aging biology. In 95% of cancer cases, age is the primary risk factor. Medicine that ignores this connection misses vital opportunities.
The vision of oncological senolytics is to turn cancer from a deadly disease into a manageable chronic condition. Not just to eliminate tumors when they appear, but to slow their emergence and prevent relapse after treatment. This is the frontier of aging medicine in 2026, and at the current pace of research, we will have approved drugs for this approach within 5-7 years.
The big lesson: Biology is not separate fields. Zombie cells, considered marginal in the field of aging just a decade ago, are now at the heart of the fight against cancer. When basic research merges with advanced medicine, breakthroughs emerge that would not be possible in each field alone.
References:
Donga Science - Zombie Cells Emerge as Dual-Action Target for Future Cancer Therapies (2026)
Nature Reviews Cancer - Senolytic approaches in oncology
💬 תגובות (0)
היו הראשונים להגיב על המאמר.